

## I. AMENDMENTS

Please cancel claims 15 to 17, 23, and 27 without prejudice.

Upon entry of the present amendment, the status of the claims will be as follows:

1. (Previously amended) A method for detecting the presence of a mammalian mutant target nucleic acid which contributes to the etiology of a neoplasm, in a tumor margin tissue specimen, wherein the specimen is external to a primary neoplasm and the specimen does not exhibit morphological characteristics indicative of neoplastic pathology, and the mutant target nucleic acid is present in the primary neoplasm and the specimen, the method comprising extracting nucleic acid present in the specimen and detecting the presence of the mutant target nucleic acid, wherein the mutant target nucleic acid is selected from APC, DCC, NF1, NF2, RET, VHL, and WT-1.

2. (Previously amended) The method of claim 1, further comprising, prior to detecting the presence of the mutant target nucleic acid, amplifying the nucleic acid present in the specimen to produce an amplified nucleic acid, wherein said detecting comprises detecting the presence of the mutant target nucleic acid in the amplified nucleic acid.

3. (Previously amended) The method of claim 2, wherein said amplifying is by means of oligonucleotides that hybridize to flanking regions of the mutant target nucleic acid.

4. (Previously amended) The method of claim 1, wherein the mutant target nucleic acid contains a mutation selected from the group consisting of a restriction fragment length polymorphism, a nucleic acid deletion, and a nucleic acid substitution.

5 and 6. (Cancelled)

7. (Previously amended) The method of claim 1, wherein the neoplasm is a neoplasm of the head.

8. (Previously amended) The method of claim 1, wherein the neoplasm is a neoplasm of the neck.

9. (Previously amended) The method of claim 1, wherein the neoplasm is a benign neoplasm.

10. (Previously amended) The method of claim 1, wherein the neoplasm is a malignant neoplasm.

11. (Previously amended) The method of claim 2, further comprising, prior to detecting the presence of the mutant nucleic acid, cloning the amplified nucleic acid, wherein said detecting comprises detecting the presence of the mutant target nucleic acid in the amplified nucleic acid.

12. (Previously amended) A method for detecting metastases in a subject having an excised tumor, the method comprising:

- a) isolating tissue from a surgical margin adjacent to the excised tumor;
- b) applying to said tissue an oligonucleotide that specifically hybridizes to a neoplastic nucleic acid having a mutant nucleotide sequence, wherein the neoplastic nucleic acid is selected from APC, DCC, NF1, NF2, RET, VHL, and WT-1; and
- c) detecting the presence of said neoplastic nucleic acid, wherein the presence of said neoplastic nucleic acid indicates metastases.

13. (Original) The method according to claim 12 wherein no more than an average of about one out of every ten thousand cells of said tissue have a neoplastic nucleic acid.

14. (Original) The method according to claim 12 wherein said tissue appears normal under a microscope.

15 to 17. (Cancelled)

18. (Previously amended) A method for detecting a mammalian target neoplastic nucleic acid having a mutant nucleotide sequence in a tissue specimen which is external to a primary neoplasm, comprising extracting nucleic acid present in the specimen to obtain extracted nucleic acid, and detecting the presence of the target neoplastic nucleic acid in the extracted nucleic acid, wherein the target neoplastic nucleic acid is selected from APC, DCC, NF1, NF2, RET, VHL, and WT-1.

19. (Previously amended) A method for detecting a mammalian target neoplastic nucleic acid having a mutant nucleotide sequence in a tumor margin tissue specimen which is external to a primary neoplasm, comprising extracting nucleic acid present in the specimen to obtain extracted nucleic acid, and detecting the presence of the target neoplastic nucleic acid in the extracted nucleic acid, wherein the target neoplastic nucleic acid is selected from APC, DCC, NF1, NF2, RET, VHL, and WT-1.

20. (Previously amended) A method for detecting the presence of a mammalian mutant target nucleic acid which contributes to the etiology of a neoplasm, in a lymph node tissue specimen, wherein the specimen is external to a primary neoplasm and the specimen does not exhibit morphological characteristics indicative of neoplastic pathology, and the mutant target nucleic acid is present in the primary neoplasm and the specimen, the method comprising

extracting nucleic acid present in the specimen and detecting the presence of the mutant target nucleic acid, wherein the mutant target nucleic acid is selected from APC, DCC, NF1, NF2, RET, VHL, and WT-1.

21. (Previously amended) The method of claim 20, further comprising, prior to detecting the presence of the mutant target nucleic acid, amplifying the nucleic acid present in the specimen to produce an amplified nucleic acid, wherein said detecting comprises detecting the presence of the mutant target nucleic acid in the amplified nucleic acid.

22. (Previously added) The method of claim 20, wherein the mutant target nucleic acid contains a mutation selected from the group consisting of a restriction fragment length polymorphism, a nucleic acid deletion, and a nucleic acid substitution.

23. (Cancelled)

24. (Previously added) The method of claim 20, wherein the neoplasm is a neoplasm of the head or a neoplasm of the neck.

25. (Previously amended) A method for detecting metastases in a subject having an excised tumor, the method comprising:

a) isolating tissue from a lymph node, which is external to a primary neoplasm and does not exhibit morphological characteristics indicative of neoplastic pathology;

b) applying to said tissue an oligonucleotide that specifically hybridizes to a neoplastic nucleic acid having a mutant nucleotide sequence, wherein the neoplastic nucleic acid is selected from APC, DCC, NF1, NF2, RET, VHL, and WT-1; and

c) detecting the presence of said neoplastic nucleic acid, wherein the presence of said neoplastic nucleic acid indicates metastases.

In re Application of  
David Sidransky  
U.S. Serial No.: 09/420,433  
Filed: October 12, 1999  
Page 6

PATENT  
Attorney Docket No.: JHU1180-1

26. (Previously added) The method of claim 25, wherein no more than an average of about one out of every ten thousand cells of said tissue have a neoplastic nucleic acid.

27. (Cancelled)